[Skip to Navigation]
Views 50
Citations 0
In This Issue of JAMA Otolaryngology
April 2018

Highlights

JAMA Otolaryngol Head Neck Surg. 2018;144(4):283. doi:10.1001/jamaoto.2017.1946

No studies to date have compared outcomes of onabotulinim toxin A treatment for different laryngeal movement disorders. Patel et al conducted a retrospective cohort study of 548 patients who received onabotulinim toxin A injections to compare the outcomes of patients with adductor spasmodic dysphonia (ADSD), ADSD with lateral laryngeal tumor (LT), and lateral LT without ADSD. They found that patients with ADSD had the most good voice days and the highest percentage of maximally beneficial injections. The authors conclude that onabotulinim toxin A injections are effective for all 3 laryngeal movement disorders, but demonstrate the highest efficacy with ADSD.

Add or change institution
×